7 research outputs found
Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue
Aim: To study the efficacy of autovaccine in the treatment of gastric cancer and significance of molecular factors having prognostic values for disease outcome to evaluate its efficacy in clinical setting. Patients and Methods: 150 patients with histologically proven adenocarcinoma of the stomach of stages II, III or IV were enrolled into study. 86 patients have been treated with autovaccine (AV) after operation. Expression of p53, Bcl-2, receptors of tyrosine kinase, vascular endothelial growth factor (VEGF), Π-cadherin, Ξ±-catenin and Ξ²-catenin was determined in paraffin embedded tumor samples by means of immunohistochemical method with the use of respective monoclonal antibodies. Results: It was shown that application of AV has resulted in the increase of 3-year overall survival of patients having stage III of disease by more than 30%, but those having stage IV β only around 14%. The increase of 3-year overall survival of patients with metastases in lymph nodes (N1β2) was observed also in more than 30%. It has been suggested the optimal phenotype for vaccine application: Ρ53(+), EGFR(+), HER-2 neu (+), Ξ²-catenin (+), VEGF(+) and Bcl-2(+) with no dependence on E-cadherin and Ξ±-catenin presence. Conclusion: It was determined that the best effect of AV application is observed in patients with category Π’3β4, poorly-differentiated tumors, metastases in lymph nodes (N1β2), but without distant metastases (Π0). Gastric cancer patients with p53, EGFR, HER-2/neu, Ξ²-catenin, VEGF and Bcl-2-positive tumors are the favorable group for the treatment with AV in the adjuvant regime
Elevation of efficacy of cancer vaccine combined with interferon and inducer of endogeneous interferon synthesis amixin
Aim: To study in vivo efficacy of combined administration of cancer vaccine (CV), interferon (IFN) and inducer of endogenous IFN β amixin. Materials and Methods: Sarcoma-37 cells were transplanted to female Balb/c mice. For the treatment, CV prepared from sarcoma-37 cells with the use of cytotoxic lectines from B. subtilis B-7025, murine IFN and amixin or their combinations were used. IFN production, content of circulating immune complexes and level of specific IgG antibodies in blood serum were determined by standard immunologic methods. Results: Using solid form of sarcoma-37 it has been shown that introduction of IFN and amixin significantly elevated efficacy of vaccine therapy, in particular index of tumor growth inhibition reach 89.2% and 81.7%. Upon combined use of CV and IFN or CV and amixin (25 mg/kg) respectively. Significant prolongation of average life span of the animals treated with CV and IFN or CV and amixin (25 mg/kg) has been registered (up to 92.7 Β± 10.4 and 95.0 Β± 6.2 days respectively, vs 46.8 Β± 1.5 days for control animals). Conclusion: Obtained results have shown expediency of the development of schemes for combined introduction of CV with exogenous IFN, and with inducer of endogenous IFN (amixin) for elevation of efficacy of vaccine therapy.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡ
Π΅ΠΌΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ (CV) Ρ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½ΠΎΠΌ
(ΠΠ€Π) ΠΈ ΠΈΠ½Π΄ΡΠΊΡΠΎΡΠΎΠΌ ΡΠ½Π΄ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΠ€Π β Π°ΠΌΠΈΠΊΡΠΈΠ½ΠΎΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΡΠ°ΡΠΊΠΎΠΌΡ-37 ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π»ΠΈ
ΠΌΡΡΠ°ΠΌ-ΡΠ°ΠΌΠΊΠ°ΠΌ Balb/c. ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ CV, ΠΏΡΠΈΠ³ΠΎΡΠΎΠ²Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°ΡΠΊΠΎΠΌΡ-37 Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΡΠΈΠ½ΠΎΠ² B. subtilis B-7025, ΠΌΡΡΠΈΠ½ΡΠΉ ΠΠ€Π (1000 Π΅Π΄.) ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½ (10 ΠΈ 25 ΠΌΠ³/ΠΊΠ³). ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
Π²ΠΊΠ»ΡΡΠ°Π»ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΡΠΈΡΡΠΎΠ² ΠΠ€Π, ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡΠΈΡ
ΠΈΠΌΠΌΡΠ½Π½ΡΡ
ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² ΠΈ ΡΡΠΎΠ²Π½Ρ
ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
IgG-Π°Π½ΡΠΈΡΠ΅Π». Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Π½Π° ΠΌΠΎΠ΄Π΅Π»ΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΡΠ°ΡΠΊΠΎΠΌΡ-37 ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ
ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠ€Π ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ, ΠΏΡΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ CV ΠΈ ΠΠ€Π ΠΈΠ½Π΄Π΅ΠΊΡ ΡΠΎΡΠΌΠΎΠΆΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΎΡΡΠ° (ΠΠ’Π) Π΄ΠΎΡΡΠΈΠ³Π°Π» 89,2%; ΠΏΡΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ CV
ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½Π° (25 ΠΌΠ³/ΠΊΠ³) ΠΠ’Π ΡΠΎΡΡΠ°Π²ΠΈΠ» 81,7%. ΠΠ°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΡΠ΅Π΄Π½Π΅ΠΉ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ
ΠΆΠΈΠ·Π½ΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
CV Ρ ΠΠ€Π ΠΈΠ»ΠΈ Π°ΠΌΠΈΠΊΡΠΈΠ½ΠΎΠΌ (25 ΠΌΠ³/ΠΊΠ³), Π΄ΠΎ 92,7 Β± 10,4 ΠΈ 95,0 Β± 6,2 ΡΡΡ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠΎ
ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠ°ΠΊΠΎΠΉ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΌΡΡΠ΅ΠΉ (46,8 Β± 1,5 ΡΡΡ, p < 0,05). ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ
ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡ
Π΅ΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ CV ΠΊΠ°ΠΊ Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΡΠΊΠ·ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΠ€Π, ΡΠ°ΠΊ ΠΈ Ρ ΠΈΠ½Π΄ΡΠΊΡΠΎΡΠΎΠΌ
ΡΠ½Π΄ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΠ€Π (Π°ΠΌΠΈΠΊΡΠΈΠ½), ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Antitumor and antimetastatic activities of vaccine prepared from cisplatin-resistant lewis lung carcinoma
To study antitumor and antimetastatic activities of antitumor vaccine (ATV) prepared from cisplatin (CP) sensitive and resistant strains of Lewis lung carcinoma (LLC). Methods: The inhibition of tumor growth, and the mean survival time of the tumor-bearing animals, the number and the volume of metastases were measured as the indices of ATV efficacy. The activity of cytotoxic T-lymphocytes and natural killer cells, peritoneal macrophages (Mph), the level of tumor necrosis factor and the total proteolytic activity of blood plasma (PA) were assessed. Results: ATV from CP resistant LLC prepared using cytolectin (CL) of Π. subtilis Π-7025 significantly inhibited growth of CP resistant tumors (by 52%) and increased mean survival time (MST) of animals (by 44.6%). The index of metastasis inhibition for ATV prepared from CP sensitive or resistant LLC was 154.5% and 227.0%, respectively. In all vaccine-treated animals, Mph activity was shown to be significantly increased. In spite of high antitumor and antimetastatic effects of ATV prepared from CP resistant LLC, PA in plasma of animals inoculated with CP resistant LLC was increased significantly upon vaccine administration
Experimental study of the efficacy of combined use of cancer vaccine and interferon
Aim: To study in in vivo model the efficacy of combined scheme of administration of cancer vaccine (CV) and interferon (IFN). Materials and Methods: Lewis lung carcinoma (LLC) was transplanted to male C57Bl mice. For treatment, CV prepared from LLC cells with the use of cytotoxic lectins of B. subtilis B-7025, and preparation of murine IFN-alpha were used. Therapeutic effect was evaluated by measurement of tumor volume and analysis of average life span (ALS) of treated animals. Immunologic study included determination of antitumor cytotoxicity of T-lymphocytes (CTL) and natural killer (NK) cells by radiometric method, functional activity of peritoneal macrophages (MP) β by colorimetric test with nitroazole blue, and evaluation of titers of tumor necrosis factor (TNF) and interleukins-1 and -2 (IL-1, 2). Results: It has been shown that the use of IFN preparation significantly elevated efficacy of vaccine therapy of solid form of LLC: duration of latent period of tumor growth elevated by 25%, ALS β by 28%, index of tumor growth inhibition β by 35β40%. Upon combined use of CV and IFN, significant activation of the cells β effectors of nonspecific immune defense (MP), and specific one (CTL) was observed. Conclusion: The obtained results evidence on perspectiveness of the development of combined schemes of administration of CV and IFN for elevation of the efficacy of vaccine therapy.Π¦Π΅Π»Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡ
Π΅ΠΌΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ (ΠΠ)
ΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π° (ΠΠ€Π). ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΡΡΠΈΡ (ΠΠΠ) ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΌΡΡΠ°ΠΌ-ΡΠ°ΠΌΡΠ°ΠΌ C57Bl.
ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΠ, ΠΏΡΠΈΠ³ΠΎΡΠΎΠ²Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ ΠΠΠ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΡΠΈΠ½ΠΎΠ² B. subtilis B-7025,
ΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΌΡΡΠΈΠ½ΠΎΠ³ΠΎ ΠΠ€Π. Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΡΡΠ΅ΠΌ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΠ±ΡΠ΅ΠΌΠ° ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ΅Π΄Π½Π΅ΠΉ
ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΆΠΈΠ·Π½ΠΈ ΠΎΠΏΡΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
. ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ°Π»ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ
ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² (Π¦Π’Π) ΠΈ ΠΏΡΠΈΡΠΎΠ΄Π½ΡΡ
ΠΊΠΈΠ»Π»Π΅ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΠΠ) ΡΠ°Π΄ΠΈΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ; ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ
Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² (ΠΡ) Π² ΠΊΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΠ‘Π’-ΡΠ΅ΡΡΠ΅; ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΈΡΡΠΎΠ² ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π°
ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (Π€ΠΠ), ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½ΠΎΠ²-1 ΠΈ -2. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠ€Π ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΠΌΠΎΠ΄Π΅Π»ΡΠ½ΠΎΠΉ ΠΠΠ: Π½Π° 25% ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π»Π°ΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ
ΠΏΠ΅ΡΠΈΠΎΠ΄Π°, Π½Π° 28% β ΡΡΠ΅Π΄Π½ΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΌΡΡΠ΅ΠΉ, Π½Π° 35β40% β ΠΈΠ½Π΄Π΅ΠΊΡ ΡΠΎΡΠΌΠΎΠΆΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΎΡΡΠ°. ΠΡΠΈ
ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΠ ΠΈ ΠΠ€Π ΠΎΡΠΌΠ΅ΡΠ°ΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ-ΡΡΡΠ΅ΠΊΡΠΎΡΠΎΠ² ΠΊΠ°ΠΊ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ
(ΠΡ), ΡΠ°ΠΊ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ (Π¦Π’Π) ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π·Π°ΡΠΈΡΡ. ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ
ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡ
Π΅ΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΠ Ρ ΠΠ€Π, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΡ
ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Use of xenogeneic vaccine modified with embryonal nervous tissue antigens in the treatment of B16βmelanoma-bearing mice
The aim of the work was experimental study of anticancer efficacy of xenogeneic cancer vaccine (XCV) developed on the basis of rat embryonic nervous tissue and protein-containing metabolite of Bacillus subtilis Π-7015 (70 kDa), in Π-16 melanoma-bearing Π‘57Bl/6 mice. Methods: Immunological methods and methods of experimental oncology were used. Effects of XCV on primary and secondary organs of immune system of experimental animals, its anticancer and antimetastatic efficacy were evaluated. Results: It has been shown that XCV did not induced toxic effects on organism, and did not caused inflammatory reactions. The relation between the degree of XCV anticancer efficacy with the regimen of its use and the presence of primary tumor has been analyzed. It has been demonstrated that the developed XCV possesses significant antimetastatic activity if it is used after surgical removal of the primary tumor: in this case lung metastasis inhibition index reached 97.4%. Conclusion: High immunogenecity of new XCV creates perspectives for detailed study of its mechanisms of action. Key Words: oncofetal antigens, xenogeneic cancer vaccine, Π-16 melanoma, immunotoxicity, effectors of anticancer defence
Cytotoxic activity of immune cells following administration of xenogeneic cancer vaccine in mice with melanoma B-16
Aim: To study the effects of xenogeneic cancer vaccine (XCV) developed on the basis of nervous tissue antigen from rat embryo of late gestation period and protein-containing metabolite of Bacillus subtilis with molecular weight of 70 kDa, on specific and unspecific antitumor reactions of cellular and humoral chains of immune system, and to analyze possible mechanisms of its antimetastatic action. Materials and Methods: XCV was administered triply with 3-day intervals after surgical removal of experimental melanoma Π-16 in C57Bl/6 mice. Cytotoxic activity (CTA) of splenocytes against target cells Π-562 as well as CTA of splenocytes, peritoneal macrophages (PM) and blood serum against melanoma Π-16 target cells were determined using ΠΠ’Π’ test. The content of circulating immune complexes (CIC) in blood serum was evaluated by precipitation reaction. Results: Immunologic effects of XCV vaccination in experimental animals with surgically removed melanoma B-16 in comparison with similarly treated unvaccinated mice were as follows: prevention of medium molecular weight CIC accumulation in blood serum during all observation period, significant increase (Ρ < 0.05) of CTA of effectors of unspecific antitumor immunity (natural killer cells β NK β by 25.5 Β± 1.7 vs 12.5 Β± 5.4%, and PM β by 37.3 Β± 0.6 vs 32.0 Β± 0.9%, respectively) at 37th day after the surgery, and also preservation of functional activity of specific cytotoxic lymphocytes at the level of intact control. Conclusion: The results of the study allow propose that antimetastatic effect of XCV vaccination could be based on increased CTA of NK and PM, and preservation of CTL functional activity at late terms after surgical removal of B-16 primary tumors. Key Words: xenogeneic cancer vaccine, melanoma Π-16, natural killer cells, macrophages, cytotoxic lymphocytes, cytotoxic activity, antimetastatic activity
CYTOTOXIC ACTIVITY OF IMMUNE CELLS FOLLOWING ADMINISTRATION OF XENOGENEIC CANCER VACCINE IN MICE WITH MELANOMA B-16
Aim: To study the effects of xenogeneic cancer vaccine (XCV) developed on the basis of nervous tissue antigen from rat embryo of late gestation period and protein-containing metabolite of Bacillus subtilis with molecular weight of 70 kDa, on specific and unspecific antitumor reactions of cellular and humoral chains of immune system, and to analyze possible mechanisms of its antimetastatic action. Materials and Methods: XCV was administered triply with 3-day intervals after surgical removal of experimental melanoma Π-16 in C57Bl/6 mice. Cytotoxic activity (CTA) of splenocytes against target cells Π-562 as well as CTA of splenocytes, peritoneal macrophages (PM) and blood serum against melanoma Π-16 target cells were determined using ΠΠ’Π’ test. The content of circulating immune complexes (CIC) in blood serum was evaluated by precipitation reaction. Results: Immunologic effects of XCV vaccination in experimental animals with surgically removed melanoma B-16 in comparison with similarly treated unvaccinated mice were as follows: prevention of medium molecular weight CIC accumulation in blood serum during all observation period, significant increase (Ρ < 0.05) of CTA of effectors of unspecific antitumor immunity (natural killer cells β NK β by 25.5 Β± 1.7 vs 12.5 Β± 5.4%, and PM β by 37.3 Β± 0.6 vs 32.0 Β± 0.9%, respectively) at 37th day after the surgery, and also preservation of functional activity of specific cytotoxic lymphocytes at the level of intact control. Conclusion: The results of the study allow propose that antimetastatic effect of XCV vaccination could be based on increased CTA of NK and PM, and preservation of CTL functional activity at late terms after surgical removal of B-16 primary tumors. Key Words: xenogeneic cancer vaccine, melanoma Π-16, natural killer cells, macrophages, cytotoxic lymphocytes, cytotoxic activity, antimetastatic activity